Epstein Secrets

From: Sultan Bin Sulayem To: Jeffrey Epstein <[email protected]> Subject: Fwd: FDA Approved a Potent and Pricey Cholesterol lowering drug today Date: Fri, 24 Jul 2015 20:37:24 +0000 Have

From: Sultan Bin Sulayem To: Jeffrey Epstein <[email protected]> Subject: Fwd: FDA Approv

From: Sultan Bin Sulayem To: Jeffrey Epstein <[email protected]> Subject: Fwd: FD

ed muscle enzymes. "Dehspite significant progress over the last decades, high cholesterol remains a leading concern in the U.S. and globally," said Olivier Brandicourt, M . , Chief Executive Officer, Sanofi. "Praluent demonstrates the power of the Sanofi and Regeneron alliance to deliver a first-in-class thera

From: Sultan Bin Sulayern Sent: 7/24/2015 8:37:24 PM To: Jeffrey Epstein [[email protected]] Subject: Fwd: FDA Approved a Potent and Pricey Cholesterol lowering drug today Importance: — High Have you heard of this co

Sulayern Sent: 7/24/2015 8:37:24 PM To: Jeffrey Epstein [[email protected]] Subject: Fwd: FDA Approve

ted muscle enzymes. "Dehspite significant progress over the last decades, high cholesterol remains a leading concern in the U.S. and globally," said Olivier Brandicourt, M.D., Chief Executive Officer, Sanofi. "Praluent demonstrates the power of the Sanofi and Regeneron alliance to deliver a first-in-class therapy in

From: jeffrey E. [[email protected]] Sent: 7/24/2015 8:47:39 PM To: Sultan Bin Sulayern Subject: Re: FDA Approved a Potent and Pricey Cholesterol lowering drug t

ted muscle enzymes. "Dehspite significant progress over the last decades, high cholesterol remains a leading concern in the U.S. and globally," said Olivier Brandicourt, M.D., Chief Executive Officer, Sanofi. "Praluent demonstrates the power of the Sanofi and Regeneron alliance to deliver a first-in-class therapy in